



Determination of Antibiotic Resistance Profile and Virulence Genes in *Escherichia coli* Isolates from Palestinian Patients

Ghaleb Adwan^{1*}

¹*Department of Biology and Biotechnology, An-Najah National University, Nablus, Palestine.*

Author's contribution

The sole author designed, analysed, interpreted and prepared the manuscript.

Article Information

DOI: 10.9734/JAMB/2019/v19i130183

Editor(s):

(1) Dr. Simone Aquino, Instituto de Pesquisas Energéticas e Nucleares (IPEN), Brazil.

Reviewers:

(1) Zumaana Rafiq, Dr. M.G.R. Educational And Research Institute, India.

(2) Teresa Fasciana, University of Palermo, Italy.

Complete Peer review History: <http://www.sdiarticle4.com/review-history/52606>

Original Research Article

Received 05 September 2019
Accepted 09 November 2019
Published 20 November 2019

ABSTRACT

Introduction: *Escherichia coli* (*E. coli*) is considered one of the most frequent intestinal and extraintestinal pathogen.

Methods: A total of 49 isolates of *E. coli* were collected from different clinical samples, from different hospitals in Northern West Bank-Palestine, during January-March 2019.

Aims: To detect the distribution of Type III secretion system (T3SS) genes, class 1, 2 and 3 integrons, virulence factors (*fyuA*, *papGIII*, *iutA* and *sfafoc*) using multiplex PCR and antibiotic resistance using disc diffusion method.

Results: In this study, *E. coli* isolates showed high resistance rate against different types of antibiotics and 71.4% of the isolates were multidrug resistant (MDR). Only class 1 integron was detected in these isolates with prevalence 57%, and 65.7% of MDR isolates carried integron genes. The prevalence of T3SS genes was 0.0%. In addition, results of this study showed that the prevalence of virulence genes *papGIII*, *sfafoc*, *fyuA* and *iutA* was 4.1%, 40%, 64%, and 79.6%, respectively.

Conclusions: The isolates of *E. coli* showed high resistance rate against different types of antibiotics. The co-occurrence of class 1 integrons and antimicrobial resistance genes in these isolates is an additional threat for spread of the antimicrobial resistance traits which may further

*Corresponding author: E-mail: adwang@najah.edu;

complicate future strategies for treatment the infections caused by this pathogen. In addition, *E. coli* isolated from Palestinian patients showed one or more virulence factors that could increase their pathogenic potential.

Keywords: *Escherichia coli*; class 1 integrons; virulence factors; antibiotic resistance; multidrug resistance.

1. INTRODUCTION

Most *E. coli* strains are harmless commensals of the human and animal intestine, but some strains are capable of causing a variety of different diseases. There are several pathotypes of *E. coli* which include: Enteropathogenic *E. coli* (EPEC), Atypical Enteropathogenic *E. coli* (A-EPEC), Enterotoxigenic *E. coli* (ETEC), Enterohemorrhagic *E. coli* (EHEC), Enteroinvasive *E. coli* (EIEC), Diffusely Adherent *E. coli* (DAEC), Enteroaggregative *E. coli* (EAEC), Shiga toxin-producing *E. coli* (STEC) and Extraintestinal Pathogenic *E. coli* (ExPEC) which includes Uropathogenic *E. coli* strains [1].

Type III secretion system (T3SS) is considered to be a one of these vital virulence factors, which is present in several pathogenic microorganisms particularly Gram-negative bacilli. The clinical spectrum of disease caused by T3SS-containing pathogens is remarkably broad. This complex is capable of injecting certain effector secretion proteins (toxins) into the host cell cytoplasm that then modulate its functions [2]. The T3SS is composed of three separate protein complexes: the secretion apparatus, the translocation or targeting apparatus, and the secreted toxins (effector proteins) and their cognate chaperones [3]. In EPEC and EHEC, T3SS encoded within the loci of enterocyte effacement (LEE). There are 5 major operons (LEE1 to LEE5), which are responsible for encoding a T3SS secreted proteins, chaperones, and regulators. The *LEE4* encodes the translocators EspA, EspB, EspD, and a chaperone for EspD (CesD2) [4]. The prevalence of *espA*, *espD* and *espB* genes in clinical *E. coli* isolates has been previously studied. It was found that the prevalence of *espA*, *espD* and *espB* among STEC was 63%, 67% and 61%, respectively, among EPEC was 55%, 100% and 100% for *espA*, *espD* and *espB*, respectively. The prevalence in EIEC strains for these genes was 50%. However, these genes were not detected in ETEC and EAEC strains [2]. In a study carried out in India on 67 STEC, 5 EPEC and 22 ETEC strains were isolated from 256 rectal swabs from yaks. The *aspB* gene was detected in two EPEC isolates (10%) only, while not detected in the STEC or ETEC isolates [5].

Five classes of integrons are known to play a role in the dissemination of antibiotic determinants to aminoglycosides and β -lactams among Gram negative species, and the most extensively studied was class 1 integrons [6,7]. In *E. coli*, the prevalence of integrons has been reported by several authors. These studies showed that the prevalence of integrons ranged from 22%-80% [8-11].

The pathogenicity of a given *E. coli* strain is mainly determined by specific virulence factors which include adhesion (fimbriae or pili), invasions, toxins (exotoxins and endotoxins), siderophores, capsule and flagella. Iron is an essential factor for pathogenicity of *E. coli* strains. Products of yersiniabactin (*fyuA*) and aerobactin (*iutA*) genes are among the most common iron acquiring systems of pathogenic and nonpathogenic *E. coli*. P-fimbrial adhesins in *E. coli* enable the colonization of host tissues. P fimbriae play a critical role in the development of urinary tract infections (UTIs). The P-fimbrial-tip adhesin, which is encoded by *papG*, attaches directly to host cells [12]. The class II G adhesin is associated with pyelonephritis and bacteremia, while the class III G adhesin sequence is associated with cystitis, although they have been found in pyelonephritis and bacteremia. The *PapGI* strains might have a larger prevalence among fecal isolates [13]. The two genetic determinants *sfa* and *foc*, coding for the S fimbrial adhesin and F1C fimbriae, respectively, and belong to the same general group of fimbrial gene clusters. These factors represent functionally distinct adhesins in their receptor specificities but enable bacteria to attach to eukaryotic cells [14]. The ability of uropathogenic *Escherichia coli* (UPEC) to cause symptomatic UTIs is enhanced by adhesins, e.g. S fimbriae and F1C fimbriae. Adherence to the urinary tract epithelium enables the bacteria to resist the hydrodynamic forces of urine flow and to establish infection [15]. There are many studies carried out to detect the prevalence of virulence factors in *E. coli*. The prevalence of *fyuA* gene had a range from 72.2%-96% [16-19], *iutA* 39.8% -84% [16-18], *papGIII* virulence factor 10%-19.3% [13,16,20,21] and *sfa/foc* 34%-36% [16,22].

This study aimed to detect the distribution of T3SS, class 1, 2 and 3 integrons, some virulence factors (*fyuA*, *papGIII*, *iutA* and *sfa/foc*) and antibiotic resistance rate among *E. coli* isolates recovered from different clinical samples in Palestine.

2. MATERIALS AND METHODS

2.1 Sample Collection

A total of 49 isolates of *E. coli* were collected from different clinical samples (Table 1). These isolates were obtained from inpatients and outpatients from different hospitals at Northern West Bank-Palestine, during January-March 2019. These hospitals were An-Najah National University Hospital-Nablus, Alwatany Hospital-Nablus, Rafidia Hospital-Nablus, Turkey Hospital-Tubas, Thabet Hospital-Tulkarm and Darweesh Nazzal Hospital-Qalqilia. In this study, replicate isolates from the same patient were excluded. All the clinical isolates were identified using the API 20E system at the respective hospital laboratories and then confirmed using conventional methods in our microbiology research laboratory.

2.2 Antibiotic Resistance

Antimicrobial susceptibility was determined according to the Clinical and Laboratory Standard Institute (CLSI) using the disk diffusion method [23]. All *E. coli* isolates were examined for resistance to Levofloxacin (LEV) 5µg, Ciprofloxacin (CIP) 5µg, Aztreonam (ATM) 30µg, Tetracycline (TE) 30µg, Imipenem(IPM) 10µg, Ceftriaxone (CFX) 30µg, Trimethoprim/Sulfamethoxazole (SXT) 25µg, Ceftazidime (CAZ) 30µg, and Amoxicillin/clavulanic acid (AMC) 30 µg. Normal saline suspensions of all *E. coli* isolates were adjusted to the McFarland 0.5 standard and used

to inoculate Mueller Hinton agar plates. The plates were incubated at 37°C for 14-16 hrs. The zone of inhibition was measured in millimeters. Isolates were classified as resistant, intermediate or susceptible according to the criteria recommended by CLSI guidelines [23]. Strains were considered multidrug-resistant (MDR) if they were resistant to at least three different classes of the antimicrobial agents tested.

2.3 Polymerase Chain Reaction and DNA Extraction

2.3.1 DNA extraction

E. coli DNA genome was prepared for PCR according to the method described previously [24]. Briefly, cells were scraped off an overnight nutrient agar plate with a sterile loop, washed with 1 ml of 1X Tris-EDTA buffer (10 mM Tris-HCl, 1 mM EDTA [pH 8.0]), then the pellet was resuspended in 0.5 ml of sterile distilled water, and boiled for 10-15 min. The cells then were incubated on ice for 10 min. The debris was pelleted by centrifugation at 11,500 X g for 5 min. DNA concentration was determined using nanodrop spectrophotometer (Genova Nano, Jenway) and the samples were stored at -20°C until use for further DNA analysis.

2.3.2 Detection of virulence genes by multiplex PCR

Detection of gene sequences encoding for T3SS proteins (*espA*, *espB* and *espD*) was performed by the multiplex PCR using specific oligonucleotide primer sets as described previously [2]. All *E. coli* isolates were screened for the presence of integrase genes *intI1*, *intI2* and *intI3* using primers previously described [27]. The presence of *sfa/foc*, *papGIII*, *iutA*, *fyuA* virulence genes was investigated by multiplex PCR using primers described previously [28].

Table 1. A sample source of 49 *E. coli* isolates collected from different hospitals at northern west bank-Palestine

Hospital	Isolate source and no. of samples						Total
	Urine	Wound swab	Blood	Stool	Vagina	Rectal swab	
N	5	3	0	0	0	0	8
A	8	0	1	2	0	0	11
T	5	0	0	0	0	1	6
TH	4	0	1	0	0	0	5
D	4	3	0	0	2	0	9
R	10	0	0	0	0	0	10
Total	36	6	2	2	2	1	49

N: An-Najah National University Hospital-Nablus; A: Alwatany Hospital-Nablus; T: Turkey Hospital-Tubas; TH: Thabet Hospital-Tulkarm; D: Darweesh Nazzal Hospital-Qalqilia; R: Rafidia Hospital-Nablus

Table 2. Target genes for PCR amplification, amplicon size, annealing temperature, primer sequences and primer mix that were used in this study

Target gene	Primer sequence (5'→3')	Amplicon size (bp)	T _a	Primer mix	Reference
Type III secretion protein (<i>espA</i>)	espA F GTT TTT CAG GCT GCG ATT CT espA R AGT TTG GCT TTC GCA TTC TT	187	50 °C	1	[2]
Type III secretion protein (<i>espD</i>)	espD F AAA AAG CAG CTC GAA GAA CA espD R CCA ATG GCA ACA ACA GCC CA	145	50 °C	1	[2]
Type III secretion protein (<i>espB</i>)	espB F GCC GTT TTT GAG AGC CAG AA espB R AAA GAA CCT AAG ATC CCC A	106	50 °C	1	[2]
Integrase 1 (<i>intl1</i>)	intl1 F GCA TCC TCG GTT TTC TG G intl1 R GGT GTG GCG GGC TTC GTG	457bp	58°C	2	[25]
Integrase 2 (<i>intl2</i>)	intl2 F CAC GGA TAT GCGAC AAA AAG G T intl2 R GTA GCA AAC GAG TGA CGA AAT G	789bp	58°C	2	[25]
Integrase 3 (<i>intl3</i>)	intl3 F ATT GCC AAA CCT GAC TG intl3 R CGA ATG CCC CAA CAA CTC	922bp	58°C	2	[25]
<i>sfa/foc</i>	<i>sfa/foc</i> F CTC CGG AGA ACT GGG TGC ATC TTA C <i>sfa/foc</i> R CGG AGG AGT AAT TAC AAA CCT GGC A	410	60°C	3	[26]
<i>iutA</i>	<i>iutA</i> F GGC TGG ACA TCA TGG GAA CTG G <i>iutA</i> R CGT CGG GAA CGG GTA GAA TCG	300	60°C	3	[26]
<i>papGIII</i>	<i>papGIII</i> F GGC CTG CAA TGG ATT TAC CTG G <i>papGIII</i> R CCA CCA AAT GAC CAT GCC AGA C	258	60°C	3	[26]
<i>fyuA</i>	<i>fyuA</i> F TGA TTA ACC CCG CGA CGG GAA <i>fyuA</i> R CGC AGT AGG CAC GAT GTT GTA	880	60°C	3	[26]

*T_a: Annealing temperature

Primer sequences used in this study and size of amplicons are presented in Table 2. Master mix was performed according to primer mix described in Table 2. Each PCR reaction mix (25 μ L) was performed using 12.5 μ L of PCR premix with $MgCl_2$ (ReadyMix™ Taq PCR Reaction Mix with $MgCl_2$, Sigma), 0.4 μ M of each primer, and 3 μ L (100-200 ng) DNA template. A negative and positive controls were also included. The DNA amplification was carried out using the thermal cycler (Mastercycler personal, Eppendorf, Germany). The cycling conditions for primer mix 1 were: initial denaturation at 94°C for 3 min; followed by 40 cycles of denaturation at 94°C for 50 s, annealing at 50°C for 40 s and extension at 72°C for 1 min; followed by a single final extension step at 72°C for 5 min, for primer mix 2 were: denaturation at 94°C for 30 sec, annealing at 58°C for 30 sec, and extension at 72°C for 1 min for 30 cycles; followed by a single final extension step at 72°C for 2 min and for primer mix 3 were: initial denaturation for 4 min at 94°C followed by 25 cycles of denaturation at 94°C for 30 s, annealing at 60°C for 30 s and extension at 72°C for 1 min; followed by a single final extension step at 72°C for 5 min. The PCR products were then detected by agarose gel electrophoresis on 1.8% (w/v) agarose gel to determine the size of amplified fragments after staining with a final concentration 0.5 μ g/ml of ethidium bromide dye. The sizes of the amplicons were determined by comparing them with a 100-bp DNA ladder.

3. RESULTS

The isolates of *E. coli* in this research showed high resistance rate against Amoxicillin/Clavulanic acid (98%). However, resistance rate against other tested antibiotics has ranged from 45% to 65%. Antibiotic

resistance profile of these *E. coli* isolates is presented in Table 3. In addition, 71.4% (35/49) of the isolates were multidrug resistant.

Results of this study showed that the prevalence of T3SS genes was 0.0%. In addition, only class 1 integron was detected in *E. coli* isolates with prevalence (28/49) 57%. Results are presented in Fig. 1. Also, results showed that 65.7% (23/35) of MDR isolates carried integrons.

The current study showed that the prevalence of *papGIII*, *sfa/foc*, *fyuA* and *iutA* genes was 4.1%, 40%, 64%, 67.3% and 79.6%, respectively. Results of these virulence factors are presented in Fig. 2.

4. DISCUSSION

Results of this study showed that *E. coli* isolates had high prevalence of antibiotic resistance. In addition, results showed that 71.4% (35/49) of the isolates were multidrug resistant which is higher than reported previously [27]. This high prevalence of antibiotic resistance in Palestine may be due to selective pressure of antibiotic imposed by the high rate and misuse of antimicrobial agents could be the only major cause [27,28].

In current study, all *E. coli* isolates that had integron genes were carried only class 1 integron and none other tested classes. This result is in contrast to other reports previously published, which showed that the class 1 and 2 integrons were detected in *E. coli* isolates [9,29-31]. However, this result is in agreement with other report previously published, which showed that the class 1 integron was the only type detected among clinical *E. coli* isolates [8].

Table 3. Antibiotic resistance profile of 49 *E. coli* isolates recovered from different clinical samples

Antibiotic	Antibiotic resistance n (%)		
	S	I	R
Ciprofloxacin (5 μ g)	23 (47.0)	1 (2.0)	25 (51.0)
Levofloxacin (10 μ g)	25 (51.0)	0 (0.0)	24 (49.0)
Aztreonam (30 μ g)	21 (43.0)	2 (4.0)	26 (53.0)
Tetracycline (30 μ g)	23 (47.0)	4 (8.0)	22 (45.0)
Ceftazidime (30 μ g)	20 (41.0)	5 (10.0)	24 (49.0)
Imipenem (10 μ g)	14 (29.0)	8 (16.0)	27 (55.0)
Ceftriaxone (30 μ g)	19 (38.78)	3 (6.12)	27 (55.0)
Amoxicillin/Clavulanic acid (20/10 μ g)	1 (2.0)	0 (0.0)	48 (98.0)
Trimethoprim/Sulphamethoxazole (1.25/23.75 μ g)	17 (35.0)	0 (0.0)	32 (65.0)

n: number of isolates; *S*: susceptible; *I*: intermediate; *R*: resistant




Fig. 1. Multiplex PCR profile specific for integrons detected from *E. coli*. Lanes L for the ladder; lanes 1, 2, 4, 5 and 6 for class I integron and lane 3 for negative control




Fig. 2. Multiplex PCR profile specific for virulence genes *papGIII*, *sfa/foc*, *fyuA* and *iutA* detected from *E. coli*. lanes L for ladder, lane 1 for *fyuA* gene 880 bp and *iutA* gene 300 bp; lane 2 for *Safloc* gene 410 bp; lane 3 for *fyuA* gene 880 bp, *iutA* gene 300 bp, *papGIII* gene 258 bp and lane 4 for *iutA* gene 300 bp. A1: it is the same as B but bands are demarcated to be obvious

In addition, results of this study showed that 65.7% (23/35) of the multidrug resistant isolates had integron genes. This result is in contrast to previously published report [9], which showed that 30% of the multidrug resistant isolates harbored integrons. However, in other study [10], reported that all MDR isolates were carried integrons. Presence of integrons among multi-drug resistant isolates might be responsible for dissemination of antibiotic resistance genes [10,25]. In this study, the prevalence of integron genes among *E. coli* isolates was 57%. This result is in contrast to other study previously published [31], which showed that 80% diarrheagenic *E. coli* isolates carried integron genes. However, other studies showed lower prevalence (22%-43.56%) [8-11]. Differences in

prevalence of integrons might be due to differences in source of isolates.

The prevalence of *espA*, *espD* and *espB* genes in clinical *E. coli* isolates has been previously studied in few reports. Our results showed that the prevalence of T3SS (*espA*, *espD* and *espB*) genes was 0.0%. However, result of this study was in contrast to other previously published report, which showed that these genes are detected only in Shiga-toxigenic *E. coli* (STEC), enteropathogenic *E. coli* (EPEC) and enteroinvasive *E. coli* (EIEC) strains [2]. This may be true because most of our isolate were extraintestinal pathogenic strains. In previous published report, it was found that the prevalence of *espA*, *espD* and *espB* among STEC was 63%,

67% and 61%, respectively. The prevalence among EPEC was 55%, 100% and 100% for *espA*, *espD* and *espB*, respectively, and the prevalence in EIEC strains for these genes was 50% for each gene, while these genes were not detected in ETEC and EAEC strains [2]. In another study carried out in India on 67 STEC, 5 EPEC and 22 ETEC strains were isolated from 256 rectal swabs from yaks. The *aspB* gene was detected in two EPEC isolates (10%) only, while not detected in the STEC or ETEC isolates [5].

The prevalence of virulence genes *papGIII*, *sfa/foc*, *fyuA* and *iutA* was 4.1%, 40%, 64%, and 79.6%, respectively. The high prevalence of *fyuA* observed in the present study among the pathogenic *E. coli* was in agreement with other reports, which showed that the prevalence had a range from 72.2%-96% [16-19]. It was found that *fyuA* gene was detected in about 92% of EAEC strains and 13% among EIEC strains [32]. Also it was found that the prevalence of *fyuA* gene was 80.3% and 39.5% among pathogenic and commensal strains, respectively. The presence of *fyuA* gene within a high pathogenicity island (HPI) seemed to be associated with the pathogenesis of these strains as its presence increased the growth of the strains in site of infection [19,33]. In addition, the *fyuA* gene was found to be highly important for biofilm formation in iron-poor environments such as human urine [33]. The high prevalence of *iutA* observed in the present study among the pathogenic *E. coli* was in agreement with other reports [16,17,34], which showed that the prevalence had a range from 67%-84% among *E. coli* isolated from patients with UTIs. However, this result is in contrast to other report [19], which showed that the prevalence was 39.8% among diarrheagenic *E. coli* strains. It was found that *iutA* gene was detected in about 12% for *E. coli* isolated from fecal samples, while 67% from patients with Cystitis [17]. Also it was found that the prevalence of *iutA* gene was 65.8% and 33.7% among pathogenic and commensal strains, respectively [35]. The prevalence *papGIII* virulence factor in our *E. coli* isolates was 4.1%. However, in other studies it was reported higher than in Palestine with a range 10%-19.3% [13,16,20,21]. In other study, the prevalence was 26% and 8% in *E. coli* isolated from cystitis and fecal samples [17]. The prevalence of *sfa/foc* virulence factor among *E. coli* isolated from North Palestine was 40%. This result is in agreement with other reports which showed that prevalence had a range from 34%-36% [16,22]. It was found that *sfa/foc* gene was detected in about 11%

from *E. coli* isolated from fecal samples, while 26% from patients with Cystitis [17]. Although the exact role of S-fimbriae is not identified; however, the dissemination of bacterium within the host tissue is suggested for this adhesin [36]. The prevalence of *papGIII*, *sfa/foc*, *fyuA* and *iutA* genes may depend on sample source.

5. CONCLUSION

Results of this study showed that *E. coli* isolates had high level of resistance rate against different types of antibiotics. The co-occurrence of class 1 integrons and antimicrobial resistance genes in current study is an additional threat for spread of the antimicrobial resistance traits which may further complicate future strategies for treatment the infections caused by this pathogen. These results reinforce international knowledge on antimicrobial resistance and the high rate of multidrug resistance found invites us to encourage population awareness of the proper use of antimicrobials. In addition, *E. coli* isolated from Palestinian patients showed one or more virulence factors that could increase their pathogenic potential.

CONSENT

As per international standard, patient's informed and written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL

As per international standard written ethical approval has been collected and preserved by the author(s).

COMPETING INTERESTS

Author has declared that no competing interests exist.

REFERENCES

1. Sousa CP. The versatile strategies of *Escherichia coli* pathotypes: a mini review. J Venom Anim Toxins incl Trop Dis 2006; 12(3):363-373.
2. Cho SH, Oh KH, Kim SH, Oh HB, Park MS. Distribution of virulence genes and their association of serotypes in pathogenic *Escherichia coli* isolates from diarrheal patients in Korea. Osong Public Health Res Perspect. 2010;1(1):29-35.

3. Adwan G. Detection of Type III secretion toxins encoding-genes of *Pseudomonas aeruginosa* isolates in the West Bank-Palestine. J Adv Biol Biotechnol. 2017;11(3):1-10. Article no.JABB.31319.
4. Neves BC, Mundy R, Petrovska L, Dougan G, Knutton S, Frankel G. CesD2 of enteropathogenic *Escherichia coli* is a second chaperone for the type III secretion translocator protein EspD. Infect Immun. 2003;71:2130–2141.
5. Bandyopadhyay S, Mahanti A, Lodh C, Samanta I, Biswas TK, Tapan K, et al. The prevalence and drug resistance profile of Shiga-toxin producing (STEC), enteropathogenic (EPEC) and enterotoxigenic (ETEC) *Escherichia coli* in free ranging diarrheic and non-diarrheic yaks of West Kameng, Arunachal Pradesh, India. Vet Arh. 2015;85(5):501-510.
6. Partridge, S.R., Collis, C.M. and Hall, R.M. Class 1 integron containing a new gene cassette, *aadA10*, associated with Tn1404 from R151. Antimicrob Agents Chemother. 2002;46:2400-2408.
7. Mazel D. Integrons: agents of bacterial evolution. Nat Rev Microbiol. 2006;4:608-620.
8. Muhammad I, Uzma M, Yasmin B, Mehmood Q, Habib B. Prevalence of antimicrobial resistance and integrons in *Escherichia coli* from punjab, Pakistan. Braz J Microbiol. 2011;42:462-466.
9. Azam H, Ghezaljah SM, Mahmoud S. Prevalence of class 1 and 2 integrons among the multidrug resistant uropathogenic strains of *Escherichia coli*. Asian Biomed. 2015;9(1):49-54.
10. Ahangarkani F, Rajabnia R, Shahandashti EF, Bagheri M, Ramez M. Frequency of class 1 integron in *Escherichia coli* strains isolated from patients with urinary tract infections in north of iran. Mater Sociomed. 2015;27(1):10-12. DOI: 10.5455/msm.2014.27.10-12.
11. Odetoyin BW, Labar AS, Lamikanra A, Aboderin AO, Okeke IN. Classes 1 and 2 integrons in faecal *Escherichia coli* strains isolated from mother-child pairs in Nigeria. PLoS One. 2017;12(8):e0183383. DOI: 10.1371/journal.pone.0183383.
12. Manning SD, Zhang L, Foxman B, Spindler A, Tallman P, Marrs CF. Prevalence of known P-fimbrial G alleles in *Escherichia coli* and identification of a new adhesin class. Clin Diagn Lab Immunol. 2001;8(3): 637-640.
13. Tiba MR, Yano T, Leite Dda S. Genotypic characterization of virulence factors in *Escherichia coli* strains from patients with cystitis. Rev Inst Med Trop Sao Paulo. 2008;50(5):255-260.
14. Ott M, Hoschützky H, Jann K, Van Die I, Hacker J. Gene clusters for S fimbrial adhesin (*sfa*) and F1C fimbriae (*foc*) of *Escherichia coli*: comparative aspects of structure and function. J Bacteriol. 1988; 170(9):3983-3990.
15. Roos V, Schembri MA, Ulett GC, Klemm P. Asymptomatic bacteriuria *Escherichia coli* strain 83972 carries mutations in the *foc* locus and is unable to express F1C fimbriae. Microbiol. 2006;152(Pt6):1799-806.
16. Bonacorsi S, Houdouin V, Mariani-Kurkdjian P, Mahjoub-Messai F, Bingen E. Comparative prevalence of virulence factors in *Escherichia coli* causing urinary tract infection in male infants with and without bacteremia. J Clin Microbiol. 2006; 44(3):1156-1158.
17. Kudinha T, Kong F, Johnson JR, Andrew SD, Anderson P, Gilbert GL. Multiplex PCR-based reverse line blot assay for simultaneous detection of 22 virulence genes in uropathogenic *Escherichia coli*. Appl Environ Microbiol. 2012;78(4):1198-1202.
18. Spurbeck RR, Dinh PC Jr, Walk ST, Stapleton AE, Hooton TM, Nolan LK, Kim KS, Johnson JR, Mobley HL. *Escherichia coli* isolates that carry *vat*, *fyuA*, *chuA*, and *yfcV* efficiently colonize the urinary tract. Infect Immun. 2012;80(12):4115-4122.
19. Hajihosein-Tabrizi A, Habibi M, Tabasi M, Karam MRA. Distribution of genes encoding iron uptake systems among the *Escherichia coli* isolates from diarrheal patients of Iran. J Med Microbiol Infect Dis. 2018;6(1):25-30.
20. Petkovsek Z, Elersic K, Gubina M, Zgur-Bertok D, Starcic Erjavec M. Virulence potential of *Escherichia coli* isolates from skin and soft tissue infections. J Clin Microbiol. 2009;47(6):1811-1817.
21. Siliano PR, Rocha LA, Medina-Pestana JO, Heilberg IP. The role of host factors and bacterial virulence genes in the development of pyelonephritis caused by *Escherichia coli* in renal transplant recipients. Clin J Am Soc Nephrol. 2010; 5(7):1290-1297.
22. Tarchouna M, Ferjani A, Ben-Selma W, Boukadida J. Distribution of uropathogenic

- virulence genes in *Escherichia coli* isolated from patients with urinary tract infection. Int J Infect Dis. 2013;17(6):e450-3. DOI: 10.1016/j.ijid.2013.01.025.
23. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 27th ed. CLSI supplement. M100. Wayne, PA, USA; 2017.
 24. Adwan G, Adwan K, Jarrar N, Salama Y, Barakat A. Prevalence of *seg*, *seh* and *sei* genes among clinical and nasal *Staphylococcus aureus* isolates. Br Microbiol Res J. 2013;3(2):139-149.
 25. Shibata N, Doi Y, Yamane K, Yagi T, Kurokawa H, Shibayama K, et al. PCR typing of genetic determinants for metallo-beta-lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron. J Clin Microbiol. 2003;41(12):5407-5413.
 26. Ferjani S, Saidani M, Ennigrou S, Hsairi M, Ben Redjeb S. Virulence determinants, phylogenetic groups and fluoroquinolone resistance in *Escherichia coli* isolated from cystitis and pyelonephritis. Pathol Biol (Paris). 2012;60(5):270-274.
 27. Adwan G, Abu Jaber A. Frequency and molecular characterization of β -lactamases producing *Escherichia coli* isolated from North of Palestine. Br Microbiol Res J. 2016;11(5):1-13, Article no.BMRJ.22631.
 28. Adwan G, Shtayah A, Adwan K, Al-Sheboul S, Othman S. Prevalence and Molecular Characterization of *P. aeruginosa* Isolates in the West Bank-Palestine for ESBLs, MBLs and Integrons. J Appl Life Sci Int. 2016;8(2):1-11. [Article no. JALSI.29259] DOI:10.9734/JALSI/2016/29259.
 29. Cocchi S, Grasselli E, Gutacker M, Benagli C, Convert M, Piffaretti J-C. Distribution and characterization of integrons in *Escherichia coli* strains of animal and human origin. FEMS Immunol Med Microbiol. 2007;50:126-132.
 30. Bashir S, Sarwar Y, Haque A, Raza A. Prevalence of integrons and antibiotic resistance among uropathogenic *Escherichia coli* from Faisalabad Region of Pakistan. Arch Clin Microbiol. 2015;6(4):9.
 31. Singh T, Das S, Ramachandran VG, Wani S, Shah D, Maroof KA, Sharma A. Distribution of integrons and phylogenetic groups among enteropathogenic *Escherichia coli* isolates from children <5 years of age in Delhi, India. Front Microbiol. 2017;8:561. DOI: 10.3389/fmicb.2017.00561
 32. Schubert S, Rakin A, Karch H, Carniel E, Heesemann J. Prevalence of the "high-pathogenicity island" of *Yersinia* species among *Escherichia coli* strains that are pathogenic to humans. Infect Immun. 1998;66(2):480-485.
 33. Hancock V, Ferrière L, Klemm P. The ferric yersiniabactin uptake receptor FyuA is required for efficient biofilm formation by urinary tract infectious *Escherichia coli* in human urine. Microbiol. 2008;154:167-175.
 34. Fasciana T, Giordano G, Di Carlo P, Colomba C, Mascarella C, Tricoli MR, Calà C, Giammanco A. Virulence factors and antimicrobial resistance of *Escherichia coli* ST131 in community-onset healthcare-associated infections in Sicily, Italy. Pharmacol OnLine. 2017;Special Issue 1:12-21.
 35. Lee JH, Subhadra B, Son YJ, Kim DH, Park HS, Kim JM, et al. Phylogenetic group distributions, virulence factors and antimicrobial resistance properties of uropathogenic *Escherichia coli* strains isolated from patients with urinary tract infections in South Korea. Lett Appl Microbiol. 2016;62:84-90.
 36. Lee S, Yu JK, Park K, Oh EJ, Kim SY, Park YJ. Phylogenetic groups and virulence factors in pathogenic and commensal strains of *Escherichia coli* and their association with blaCTX-M. Ann Clin Lab Sci. 2010;40(4):361-367.

© 2019 Adwan; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
 The peer review history for this paper can be accessed here:
<http://www.sdiarticle4.com/review-history/52606>